|
1
|
Mun EJ, Babiker HM, Weinberg U, Kirson ED
and Von Hoff DD: Tumor-treating fields: A fourth modality in cancer
treatment. Clin Cancer Res. 24:266–275. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Schirrmacher V: From chemotherapy to
biological therapy: A review of novel concepts to reduce the side
effects of systemic cancer treatment (review). Int J Oncol.
54:407–419. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Remer M, White A, Glennie M, Al-Shamkhani
A and Johnson P: The use of anti-CD40 mAb in cancer. Curr Top
Microbiol Immunol. 405:165–207. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wolska-Washer A and Robak T: Safety and
tolerability of antibody-drug conjugates in cancer. Drug Saf.
42:295–314. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ovacik M and Lin K: Tutorial on monoclonal
antibody pharmacokinetics and its considerations in early
development. Clin Transl Sci. 11:540–552. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hafeez U, Parakh S, Gan HK and Scott AM:
Antibody-drug conjugates for cancer therapy. Molecules.
25(4764)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hoffmann RM, Mele S, Cheung A,
Larcombe-Young D, Bucaite G, Sachouli E, Zlatareva I, Morad HOJ,
Marlow R, McDonnell JM, et al: Rapid conjugation of antibodies to
toxins to select candidates for the development of anticancer
antibody-drug conjugates (ADCs). Sci Rep. 10(8869)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sievers EL and Senter PD: Antibody-drug
conjugates in cancer therapy. Annu Rev Med. 64:15–29.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Abdollahpour-Alitappeh M, Lotfinia M,
Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, Faghfourian
B, Sepehr KS, Abbaszadeh-Goudarzi K, Abbaszadeh-Goudarzi G, et al:
Antibody-drug conjugates (ADCs) for cancer therapy: Strategies,
challenges, and successes. J Cell Physiol. 234:5628–5642.
2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Goulet DR and Atkins WM: Considerations
for the design of antibody-based therapeutics. J Pharm Sci.
109:74–103. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yu J, Song Y and Tian W: How to select IgG
subclasses in developing anti-tumor therapeutic antibodies. J
Hematol Oncol. 13(45)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Vidarsson G, Dekkers G and Rispens T: IgG
subclasses and allotypes: From structure to effector functions.
Front Immunol. 5(520)2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hoffmann RM, Coumbe BGT, Josephs DH, Mele
S, Ilieva KM, Cheung A, Tutt AN, Spicer JF, Thurston DE, Crescioli
S and Karagiannis SN: Antibody structure and engineering
considerations for the design and function of antibody drug
conjugates (ADCs). Oncoimmunology. 7(e1395127)2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wakankar A, Chen Y, Gokarn Y and Jacobson
FS: Analytical methods for physicochemical characterization of
antibody drug conjugates. MAbs. 3:161–172. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chudasama V, Maruani A and Caddick S:
Recent advances in the construction of antibody-drug conjugates.
Nat Chem. 8:114–119. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lyu Z, Kang L, Buuh ZY, Jiang D, McGuth
JC, Du J, Wissler HL, Cai W and Wang RE: A switchable site-specific
antibody conjugate. ACS Chem Biol. 13:958–964. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Drago JZ, Modi S and Chandarlapaty S:
Unlocking the potential of antibody-drug conjugates for cancer
therapy. Nat Rev Clin Oncol. 18:327–344. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lu J, Jiang F, Lu A and Zhang G: Linkers
having a crucial role in antibody-drug conjugates. Int J Mol Sci.
17(561)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bargh JD, Isidro-Llobet A, Parker JS and
Spring DR: Cleavable linkers in antibody-drug conjugates. Chem Soc
Rev. 48:4361–4374. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tsuchikama K and An Z: Antibody-drug
conjugates: Recent advances in conjugation and linker chemistries.
Protein Cell. 9:33–46. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Pahl A, Lutz C and Hechler T: Amanitins
and their development as a payload for antibody-drug conjugates.
Drug Discov Today Technol. 30:85–89. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
McCombs JR and Owen SC: Antibody drug
conjugates: Design and selection of linker, payload and conjugation
chemistry. AAPS J. 17:339–351. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yaghoubi S, Karimi MH, Lotfinia M, Gharibi
T, Mahi-Birjand M, Kavi E, Hosseini F, Sineh Sepehr K, Khatami M,
Bagheri N and Abdollahpour-Alitappeh M: Potential drugs used in the
antibody-drug conjugate (ADC) architecture for cancer therapy. J
Cell Physiol. 235:31–64. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fu Z, Li S, Han S, Shi C and Zhang Y:
Antibody drug conjugate: The ‘biological missile’ for targeted
cancer therapy. Signal Transduct Target Ther. 7(93)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Manabe S and Yamaguchi Y: Antibody
glycoengineering and homogeneous antibody-drug conjugate
preparation. Chem Rec. 21:3005–3014. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jin Y, Schladetsch MA, Huang X, Balunas MJ
and Wiemer AJ: Stepping forward in antibody-drug conjugate
development. Pharmacol Ther. 229(107917)2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ponziani S, Di Vittorio G, Pitari G,
Cimini AM, Ardini M, Gentile R, Iacobelli S, Sala G, Capone E,
Flavell DJ, et al: Antibody-drug conjugates: The new frontier of
chemotherapy. Int J Mol Sci. 21(5510)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kantarjian HM, Kadia TM, DiNardo CD, Welch
MA and Ravandi F: Acute myeloid leukemia: Treatment and research
outlook for 2021 and the MD Anderson approach. Cancer.
127:1186–1207. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ali S, Dunmore HM, Karres D, Hay JL,
Salmonsson T, Gisselbrecht C, Sarac SB, Bjerrum OW, Hovgaard D,
Barbachano Y, et al: The EMA review of mylotarg (gemtuzumab
ozogamicin) for the treatment of acute myeloid leukemia.
Oncologist. 24:e171–e179. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
McKertish CM and Kayser V: Advances and
limitations of antibody drug conjugates for cancer. Biomedicines.
9(872)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chari RV, Miller ML and Widdison WC:
Antibody-drug conjugates: An emerging concept in cancer therapy.
Angew Chem Int Ed Engl. 53:3796–3827. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Petersdorf SH, Kopecky KJ, Slovak M,
Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ,
Stuart RK, et al: A phase 3 study of gemtuzumab ozogamicin during
induction and postconsolidation therapy in younger patients with
acute myeloid leukemia. Blood. 121:4854–4860. 2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yu B and Liu D: Gemtuzumab ozogamicin and
novel antibody-drug conjugates in clinical trials for acute myeloid
leukemia. Biomark Res. 7(24)2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Fatobene G, Souza GR, Rodrigues CA, Novis
YAS and Rocha V: Gemtuzumab ozogamicin is efficacious in attaining
complete remission in relapsed/refractory acute leukemia prior to
hematopoietic cell transplant: A case series. Hematol Transfus Cell
Ther. 43:532–536. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hitzler J and Estey E: Gemtuzumab
ozogamicin in acute myeloid leukemia: Act 2, with perhaps more to
come. Haematologica. 104:7–9. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lambert J, Pautas C, Terré C, Raffoux E,
Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant
K, et al: Gemtuzumab ozogamicin for de novo acute myeloid leukemia:
Final efficacy and safety updates from the open-label, phase III
ALFA-0701 trial. Haematologica. 104:113–119. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kayser S and Levis MJ: Updates on targeted
therapies for acute myeloid leukaemia. Br J Haematol. 196:316–328.
2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Schlenk RF, Paschka P, Krzykalla J, Weber
D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T,
Schroeder T, et al: Gemtuzumab ozogamicin in NPM1-mutated acute
myeloid leukemia: Early results from the prospective randomized
AMLSG 09-09 phase III study. J Clin Oncol. 38:623–632.
2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Baron J and Wang ES: Gemtuzumab ozogamicin
for the treatment of acute myeloid leukemia. Expert Rev Clin
Pharmacol. 11:549–559. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Horwitz S, O'Connor OA, Pro B, Trümper L,
Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F,
Domingo-Domenech E, et al: The ECHELON-2 Trial: 5-Year results of a
randomized, phase III study of brentuximab vedotin with
chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann
Oncol. 33:288–298. 2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Horwitz SM, Scarisbrick JJ, Dummer R,
Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O,
Eradat H, et al: Randomized phase 3 ALCANZA study of brentuximab
vedotin vs physician's choice in cutaneous T-cell lymphoma: Final
data. Blood Adv. 5:5098–5106. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Chen R, Herrera AF, Hou J, Chen L, Wu J,
Guo Y, Synold TW, Ngo VN, Puverel S, Mei M, et al: Inhibition of
MDR1 overcomes resistance to brentuximab vedotin in Hodgkin
lymphoma. Clin Cancer Res. 26:1034–1044. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Di Girolamo A, Albanesi M, Sinisi A,
Nettis E, Di Bona D, Caiaffa MF and Macchia L: Rapid
desensitization for brentuximab vedotin (Adceteris®)
allergy: A case report. Clin Mol Allergy. 16(22)2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Chu Y, Zhou X and Wang X: Antibody-drug
conjugates for the treatment of lymphoma: Clinical advances and
latest progress. J Hematol Oncol. 14(88)2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Jatoi I and Pinsky PF: Breast cancer
screening trials: Endpoints and overdiagnosis. J Natl Cancer Inst.
113:1131–1135. 2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Hamilton E, Shastry M, Shiller SM and Ren
R: Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev.
100(102286)2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Derakhshani A, Rezaei Z, Safarpour H,
Sabri M, Mir A, Sanati MA, Vahidian F, Gholamiyan Moghadam A,
Aghadoukht A, Hajiasgharzadeh K and Baradaran B: Overcoming
trastuzumab resistance in HER2-positive breast cancer using
combination therapy. J Cell Physiol. 235:3142–3156. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Cesca MG, Vian L, Cristóvão-Ferreira S,
Pondé N and de Azambuja E: HER2-positive advanced breast cancer
treatment in 2020. Cancer Treat Rev. 88(102033)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Dosio F, Brusa P and Cattel L:
Immunotoxins and anticancer drug conjugate assemblies: The role of
the linkage between components. Toxins (Basel). 3:848–883.
2011.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Lombardi J, Lory P, Martin N, Mayeur D,
Combret S, Grandvuillemin A, Boulay C and Schmitt A:
Trastuzumab-emtansine induced pleural and pericardial effusions. J
Oncol Pharm Pract. 27:2041–2044. 2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Theocharopoulos C, Lialios PP, Gogas H and
Ziogas DC: An overview of antibody-drug conjugates in oncological
practice. Ther Adv Med Oncol. 12(1758835920962997)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Okines A, Irfan T, Khabra K, Smith I,
O'Brien M, Parton M, Noble J, Stanway S, Somaiah N, Ring A, et al:
Development and responses of brain metastases during treatment with
trastuzumab emtansine (T-DM1) for HER2 positive advanced breast
cancer: A single institution experience. Breast J. 24:253–259.
2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Hardy-Werbin M, Quiroga V, Cirauqui B,
Romeo M, Felip E, Teruel I, Garcia JJ, Erasun C, España S, Cucurull
M, et al: Real-world data on T-DM1 efficacy-results of a
single-center retrospective study of HER2-positive breast cancer
patients. Sci Rep. 9(12760)2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Pondé N, Aftimos P and Piccart M:
Antibody-drug conjugates in breast cancer: A comprehensive review.
Curr Treat Options Oncol. 20(37)2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Chen SC, Quartino A, Polhamus D, Riggs M,
French J, Wang X, Vadhavkar S, Smitt M, Hoersch S, Strasak A, et
al: Population pharmacokinetics and exposure-response of
trastuzumab emtansine in advanced breast cancer previously treated
with ≥2 HER2-targeted regimens. Br J Clin Pharmacol. 83:2767–2777.
2017.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Larionov AA: Current therapies for human
epidermal growth factor receptor 2-positive metastatic breast
cancer patients. Front Oncol. 8(89)2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Perez EA, de Haas SL, Eiermann W, Barrios
CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, et
al: Relationship between tumor biomarkers and efficacy in MARIANNE,
a phase III study of trastuzumab emtansine ± pertuzumab versus
trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer. 19(517)2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Perez EA, Barrios C, Eiermann W, Toi M, Im
YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA III, et
al: Trastuzumab emtansine with or without pertuzumab versus
trastuzumab with taxane for human epidermal growth factor receptor
2-positive advanced breast cancer: Final results from MARIANNE.
Cancer. 125:3974–3984. 2019.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Liu F, Ke J and Song Y: T-DM1-induced
thrombocytopenia in breast cancer patients: New perspectives.
Biomed Pharmacother. 129(110407)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Krop IE, Kim SB, González-Martín A,
LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC and Wildiers H:
TH3RESA study collaborators. Trastuzumab emtansine versus treatment
of physician's choice for pretreated HER2-positive advanced breast
cancer (TH3RESA): A randomised, open-label, phase 3 trial. Lancet
Oncol. 15:689–699. 2014.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Li BT, Michelini F, Misale S, Cocco E,
Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, et al:
HER2-mediated internalization of cytotoxic agents in ERBB2
amplified or mutant lung cancers. Cancer Discov. 10:674–687.
2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Tilly H, Morschhauser F, Sehn LH,
Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M,
Rai S, et al: Polatuzumab vedotin in previously untreated diffuse
large B-cell lymphoma. N Engl J Med. 386:351–363. 2022.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Bardia A, Tolaney SM, Punie K, Loirat D,
Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S,
et al: Biomarker analyses in the phase III ASCENT study of
sacituzumab govitecan versus chemotherapy in patients with
metastatic triple-negative breast cancer. Ann Oncol. 32:1148–1156.
2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Chu CE, Sjöström M, Egusa EA, Gibb EA,
Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, et al:
Heterogeneity in NECTIN4 expression across molecular subtypes of
urothelial cancer mediates sensitivity to enfortumab vedotin. Clin
Cancer Res. 27:5123–5130. 2021.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Lonial S, Lee HC, Badros A, Trudel S,
Nooka AK, Chari A, Abdallah AO, Callander N, Sborov D,
Suvannasankha A, et al: Longer term outcomes with single-agent
belantamab mafodotin in patients with relapsed or refractory
multiple myeloma: 13-Month follow-up from the pivotal DREAMM-2
study. Cancer. 127:4198–4212. 2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Dahlgren D and Lennernäs H: Antibody-drug
conjugates and targeted treatment strategies for hepatocellular
carcinoma: A drug-delivery perspective. Molecules.
25(2861)2020.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Takegawa N, Tsurutani J, Kawakami H,
Yonesaka K, Kato R, Haratani K, Hayashi H, Takeda M, Nonagase Y,
Maenishi O and Nakagawa K: [fam-] trastuzumab deruxtecan, antitumor
activity is dependent on HER2 expression level rather than on HER2
amplification. Int J Cancer. 145:3414–3424. 2019.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Indini A, Rijavec E and Grossi F:
Trastuzumab deruxtecan: Changing the destiny of HER2 expressing
solid tumors. Int J Mol Sci. 22(4774)2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Aoki M, Iwasa S and Boku N: Trastuzumab
deruxtecan for the treatment of HER2-positive advanced gastric
cancer: A clinical perspective. Gastric Cancer. 24:567–576.
2021.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Andrikopoulou A, Zografos E, Liontos M,
Koutsoukos K, Dimopoulos MA and Zagouri F: Trastuzumab deruxtecan
(DS-8201a): The latest research and advances in breast cancer. Clin
Breast Cancer. 21:e212–e219. 2021.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Yin O, Iwata H, Lin CC, Tamura K, Watanabe
J, Wada R, Kastrissios H, AbuTarif M, Garimella T, Lee C, et al:
Exposure-response relationships in patients with HER2-positive
metastatic breast cancer and other solid tumors treated with
trastuzumab deruxtecan. Clin Pharmacol Ther. 110:986–996.
2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai
L, Chen L, Zhu Y, Guo C, Shi J and Yu D: Novel HER2-targeting
antibody-drug conjugates of trastuzumab beyond T-DM1 in breast
cancer: Trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab
duocarmazine (SYD985). Eur J Med Chem. 183(111682)2019.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Modi S, Jacot W, Yamashita T, Sohn J,
Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, et al:
Trastuzumab deruxtecan in previously treated HER2-low advanced
breast cancer. N Engl J Med. 387:9–20. 2022.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Modi S, Saura C, Yamashita T, Park YH, Kim
SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, et al:
Trastuzumab deruxtecan in previously treated HER2-positive breast
cancer. N Engl J Med. 382:610–621. 2020.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Modi S, Park H, Murthy RK, Iwata H, Tamura
K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, et
al: Antitumor activity and safety of trastuzumab deruxtecan in
patients with HER2-low-expressing advanced breast cancer: Results
from a phase Ib study. J Clin Oncol. 38:1887–1896. 2020.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Kotani D and Shitara K: Trastuzumab
deruxtecan for the treatment of patients with HER2-positive gastric
cancer. Ther Adv Med Oncol. 13(1758835920986518)2021.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Shitara K, Bang YJ, Iwasa S, Sugimoto N,
Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, et al:
Trastuzumab deruxtecan in previously treated HER2-positive gastric
cancer. N Engl J Med. 382:2419–2430. 2020.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Perez J, Garrigós L, Gion M, Jänne PA,
Shitara K, Siena S and Cortés J: Trastuzumab deruxtecan in
HER2-positive metastatic breast cancer and beyond. Expert Opin Biol
Ther. 21:811–824. 2021.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Tsurutani J, Iwata H, Krop I, Jänne PA,
Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, et
al: Targeting HER2 with trastuzumab deruxtecan: A dose-expansion,
phase I study in multiple advanced solid tumors. Cancer Discov.
10:688–701. 2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Meric-Bernstam F, Hurwitz H, Raghav KPS,
McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R,
Burris H, Sweeney C, et al: Pertuzumab plus trastuzumab for
HER2-amplified metastatic colorectal cancer (MyPathway): An updated
report from a multicentre, open-label, phase 2a, multiple basket
study. Lancet Oncol. 20:518–530. 2019.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Kumagai K, Aida T, Tsuchiya Y, Kishino Y,
Kai K and Mori K: Interstitial pneumonitis related to trastuzumab
deruxtecan, a human epidermal growth factor receptor 2-targeting
Ab-drug conjugate, in monkeys. Cancer Sci. 111:4636–4645.
2020.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Shitara K, Baba E, Fujitani K, Oki E,
Fujii S and Yamaguchi K: Discovery and development of trastuzumab
deruxtecan and safety management for patients with HER2-positive
gastric cancer. Gastric Cancer. 24:780–789. 2021.PubMed/NCBI View Article : Google Scholar
|
